MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock and...
$215,646K
Proceeds from 2025
trinity term loan, net
$49,853K
Proceeds from issuance of
common stock pursuant...
$48,435K
Proceeds from stock
option exercises
$1,220K
Proceeds from issuance of
common stock upon...
$225K
Proceeds from common
stock issuances under...
$159K
Net cash provided by
financing activities
$274,589K
Canceled cashflow
$40,949K
Net increase
(decrease) in cash, cash...
$180,895K
Canceled cashflow
$93,694K
Prepayment of 2023 trinity
term loan
$40,612K
Other
-$337K
Stock-based compensation
$13,298K
Accrued expenses and
other liabilities
$6,289K
Research and development
license expense
$3,000K
Non-cash lease expense
$1,359K
Change in fair value of
warrant liability
$1,199K
Depreciation expense
$1,145K
Non-cash change in fair
value of term loan
$832K
Other
-$296K
Debt issuance costs
expensed under the fair...
$147K
Other
-$134K
Net cash used in
operating activities
-$93,090K
Net cash used in
investing activities
-$604K
Canceled cashflow
$27,565K
Canceled cashflow
$134K
Net loss
-$108,995K
Purchase of property,
plant and equipment
$738K
Deferred revenue
-$9,773K
Prepaid expenses and
other assets
$1,734K
Accounts payable
-$153K
Back
Back
Cash Flow
source: myfinsight.com
Taysha Gene Therapies, Inc. (TSHA)
Taysha Gene Therapies, Inc. (TSHA)